Cognition Therapeutics, Inc.
Moat Score — Cognition Therapeutics, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Zervimesine's differentiated sigma-2 receptor mechanism and Phase 2 data in both Alzheimer's and dementia with Lewy bodies are real intellectual property, but the company is tiny (14 employees) with no approved product and no proven ability to see a drug through to commercial launch. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | With only 14 employees and no manufacturing or commercial infrastructure, Cognition has no cost advantage versus deep-pocketed rivals like Eisai and Eli Lilly. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | An oral alternative to infused antibody therapies could eventually command specialty pricing if approved, but with no marketed product there is no realized pricing power today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Neurodegenerative drug therapy has no network effect between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | In dementia with Lewy bodies specifically, the lack of other approved disease-modifying options could create some first-mover prescriber loyalty if zervimesine is approved, but this is speculative until later-stage trials read out. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Cognition competes directly against Eisai's Leqembi and Eli Lilly's Kisunla, both backed by vastly larger organizations, leaving no efficient-scale protection for a 14-person clinical-stage company. |